Quad-Mix Injection is a combination medication that brings together four active ingredients to address specific medical conditions requiring enhanced therapeutic action. It is commonly used in clinical settings where multiple pathways of treatment are targeted simultaneously, offering a synergistic effect to improve patient outcomes. The formulation is designed to deliver the medication directly into the bloodstream, ensuring rapid absorption and effectiveness. Quad-Mix Injection is prescribed under strict medical supervision and is intended for individuals who need specialized treatment.

The combination of ingredients in Quad-Mix Injection works synergistically to relax the smooth muscles and dilate the blood vessels in the penis. This increased blood flow allows the penis to become firm and maintain an erection suitable for sexual activity. The solution targets multiple pathways involved in vascular response, including inhibiting enzymes that restrict blood flow and enhancing signals that promote muscle relaxation. This coordinated action helps restore sexual function in affected individuals.

Quad-Mix Injection should not be used by individuals with known allergies to any of its components or by those with severe heart, liver, or kidney conditions unless directed by a healthcare provider. It is also not suitable for individuals who are taking medications that could interact with its ingredients or worsen their condition. Patients with infections, uncontrolled high blood pressure, or certain neurological disorders should avoid this treatment unless cleared by their doctor. Regular monitoring of vital signs and lab tests may be required to ensure safe and effective use. Always disclose your full medical history before beginning treatment.

This medication may interact with nitrates, alpha-blockers, or blood pressure medications, leading to potentially serious drops in blood pressure. It may also enhance the effects of other vasodilators or erectile dysfunction treatments, increasing the risk of side effects. Patients should disclose all medications, supplements, and health conditions to their doctor to ensure safe use and to prevent harmful interactions.

Some users of Quad-Mix Injection may experience mild to moderate side effects, particularly during the early stages of treatment. Common reactions include dizziness, headache, muscle weakness, or localized pain at the injection site. In some cases, nausea, flushing, or changes in blood pressure may occur. Though rare, more serious side effects such as allergic reactions, difficulty breathing, or irregular heartbeat require immediate medical attention. Side effects are generally temporary and manageable when the treatment is administered as prescribed, but medical guidance should be sought if symptoms persist or worsen.

Quad-Mix Injection is intended for use in men and is not applicable for women, including those who are pregnant or breastfeeding. It should be stored and handled carefully to avoid accidental exposure. If there is any concern about contact with partners or children, consult a healthcare provider for safe usage and disposal methods.

Store dry powder at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Once reconstituted keep this medicine in a refrigerator between 36°F to 46°F (2°C to 8°C). Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain

1. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2. Leungwattanakij S, Flynn V, Hellstrom WJG. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am 2001;28:343-354.
3. Andersson, K.E., Pharmacology of penile erection. Pharmacol Rev, 2001. 53(3): p. 417-50.
4. Virag, R., et al., Vasoactive intestinal polypeptide release during penile erection in man. Lancet, 1982. 2(8308): p. 1166.
5. K.E., A., Pharmacology of erection: agents which initiate and terminate erection. Sex Disabil 1994. 12: p. 53–79.
6. Kirkeby, H.J., et al., [Infusion cavernosography and erectile dysfunction]. Ugeskr Laeger, 1990. 152(24): p. 1724-6.
7. Juenemann, K.P., et al., Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol, 1986. 136(1): p. 158-61.
8. Delcour, C., et al., The effect of papaverine on arterial and venous hemodynamics of erection. J Urol, 1987. 138(1): p. 187-9.
9. Mooradian, A.D., et al., Biweekly intracavernous administration of papaverine for erectile dysfunction. West J Med, 1989. 151(5): p. 515-7.
10. Dinsmore, W.W., Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Ulster Med J, 1990. 59(2): p. 174-6.
11. Keogh, E.J., et al., Treatment of impotence by intrapenile injections of papaverine and phenoxybenzamine: a double blind, controlled trial. Aust N Z J Med, 1989. 19(2): p. 108-12.
12. Viswaroop, B., A. B, and G. Gopalakrishnan, Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine. Natl Med J India, 2005. 18(6): p. 299-301.
13. Traish, A.M., et al., Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct, 1997. 7(1): p. 55-67.
14. Traish, A., et al., Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res, 1998. 10(4): p. 215-23.
15. Juenemann, K.P., et al., Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol, 1986. 136(1): p. 158-61.
16. Wespes, E., C. Rondeux, and C.C. Schulman, Effect of phentolamine on venous return in human erection. Br J Urol, 1989. 63(1): p. 95-7.
17. P.R., I., G. B., and B.L. . Human pharmacology of orally administered phentolamine, in Phentolamine in Heart Failure and Other Cardiac Disorders., in Proceedings of an International Workshop London, November 1975 T. S.H. and G. L.A., Editors. 1975, Hans Huber Publishers: Bern, Switzerland.
18. O, H., W. U, and K. U, Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impot Res, 1990. 2 (Suppl 2): p. 247–248.
19. Eardley, I., et al., Pharmacotherapy for erectile dysfunction. J Sex Med, 2010. 7(1 Pt 2): p. 524-40.
20. Dinsmore, W.W. and M.G. Wyllie, Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int, 2008. 102(8): p. 933-7.
21. Albersen, M., et al., Evaluation and treatment of erectile dysfunction. Med Clin North Am, 2011. 95(1): p. 201-12.
22. Linet, O.I. and F.G. Ogrinc, Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med, 1996. 334(14): p. 873-7.
23. Porst, H., The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol, 1996. 155(3): p. 802-15.
24. Angulo, J., et al., Rationale for the combination of PGE(1) and S-nitroso-glutathione to induce relaxation of human penile smooth muscle. J Pharmacol Exp Ther, 2000. 295(2): p. 586-93.
25. Molderings, G.J., et al., Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein by presynaptic histamine H3 receptors. Naunyn Schmiedebergs Arch Pharmacol, 1992. 346(1): p. 46-50.
26. Palmer, L.S., et al., Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol, 1994. 152(4): p. 1308-14.
27. Golub, M., et al., Metabolism of prostaglandins A1 and E1 in man. J Clin Invest, 1975. 56(6): p. 1404-10.
28. Hall, S., et al., Use of atropine sulfate in pharmacologic erections: initial experience with one year follow-up in the United States. . 1992. part 2: p. part 2, 147: 265A.
29. Montorsi, F., et al., Long-term clinical reliability of transurethral and open prostatectomy for benign prostatic obstruction: a term of comparison for nonsurgical procedures. Eur Urol, 1993. 23(2): p. 262-6.
30. Montorsi, F., et al., Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol, 1993. 149(5 Pt 2): p. 1291-5.
31. ”Prostaglandin E1/Phentolamine/Papaverine Injection Patient Information”. The Compounding Center. Web.